Targeting the endocannabinoid system: to enhance or reduce?

@article{Marzo2008TargetingTE,
  title={Targeting the endocannabinoid system: to enhance or reduce?},
  author={Vincenzo Di Marzo},
  journal={Nature Reviews Drug Discovery},
  year={2008},
  volume={7},
  pages={438-455}
}
  • V. Marzo
  • Published 1 May 2008
  • Medicine, Biology
  • Nature Reviews Drug Discovery
As our understanding of the endocannabinoids improves, so does the awareness of their complexity. During pathological states, the levels of these mediators in tissues change, and their effects vary from those of protective endogenous compounds to those of dysregulated signals. These observations led to the discovery of compounds that either prolong the lifespan of endocannabinoids or tone down their action for the potential future treatment of pain, affective and neurodegenerative disorders… 
Rehashing endocannabinoid antagonists: can we selectively target the periphery to safely treat obesity and type 2 diabetes?
  • M. Patti
  • Medicine, Biology
    The Journal of clinical investigation
  • 2010
TLDR
New data demonstrate that selective blockade of peripheral cannabinoid receptors may be a novel successful therapeutic approach for obesity-related metabolic complications in humans.
Modulating the endocannabinoid system in human health and disease – successes and failures
TLDR
Clinical trials with globally acting CB1 antagonists in obesity/metabolic syndrome, and other studies with peripherally‐restricted CB1/2 agonists and inhibitors of the endocannabinoid metabolizing enzyme in pain, have introduced unexpected complexities, suggesting that a better understanding of the pathophysiological role of the ENDOCannabinoid system is required to devise clinically successful treatment strategies.
Targeting the endocannabinoid system for gastrointestinal diseases: future therapeutic strategies
TLDR
An introduction into the functions of the endocannabinoid system in the GI tract is given, the role of the ECS in GI diseases is highlighted, and its potential pharmacological exploitation is addressed.
Enhanced endocannabinoid tone as a potential target of pharmacotherapy
Elevating endocannabinoid levels: pharmacological strategies and potential therapeutic applications
  • R. Pertwee
  • Biology, Chemistry
    Proceedings of the Nutrition Society
  • 2013
The endocannabinoid system consists of cannabinoid CB1 and CB2 receptors, of endogenous agonists for these receptors known as ‘endocannabinoids’, and of processes responsible for endocannabinoid
Role of the Endocannabinoid System in Systems Toxicity
TLDR
The scientific knowledge regarding the modulation of the endogenous cannabinoid system and its effect on disease pathophysiology has been significantly improved in the last 20 years, suggesting their important regulatory role.
Endocannabinoid biosynthesis and inactivation, from simple to complex.
The Endocannabinoid System: A Potential Target for the Treatment of Various Diseases
TLDR
This manuscript in-depth review will investigate the potential of the ECS in the treatment of various diseases, and to put forth the suggestion that many of these secondary metabolites of Cannabis sativa L. sativa may also have potential as lead compounds in the development of cannabinoid-based pharmaceuticals for a variety of diseases.
Endocannabinoid signalling and the deteriorating brain
TLDR
This work proposes a conceptual framework linking eCB signalling to the control of the cellular and molecular hallmarks of these processes, and categorizes the key components of endocannabinoid signalling that may serve as targets for novel therapeutics.
The endocannabinoid system as a target for the treatment of neuronal damage
TLDR
Cannabinoids can serve this purpose given their recognized antiexcitotoxic, antioxidant and anti-inflammatory properties, and there is an urgent need for novel neuroprotective agents.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 229 REFERENCES
The complications of promiscuity: endocannabinoid action and metabolism
TLDR
The complexity of the endocannabinoid system is highlighted, based on the promiscuous nature of ECLs and their metabolites, as well as the synthetic modulators of the Endocannabinoids system.
The endocannabinoid system: a drug discovery perspective.
  • D. Piomelli
  • Biology, Chemistry
    Current opinion in investigational drugs
  • 2005
TLDR
Three opportunities to modulate a variety of pathophysiological processes, including appetite, pain and mood, are discussed here: reduction of body weight through blockade of CB1 receptors, alleviation of pain through activation of extracerebral cannabinoid receptors, and modulation of pain and anxiety through inhibition of endocannabinoid degradation.
Endocannabinoids and the regulation of their levels in health and disease
TLDR
Endocannabinoid levels appear to be transiently elevated as an adaptive reaction to re-establish normal homeostasis when this is acutely and pathologically perturbed.
The endocannabinoid system and its therapeutic exploitation
TLDR
The conditions under which the potential of targeting the endocannabinoid system might be realized in the years to come are explored.
The endocannabinoid system and gut-brain signalling.
Endocannabinoid overactivity and intestinal inflammation
TLDR
Recent data indicate that the endocannabinoid system in the small intestine and colon becomes over stimulated during inflammation in both animal models and human inflammatory disorders.
Endocannabinoids and the control of energy balance
The Endocannabinoid System as an Emerging Target of Pharmacotherapy
TLDR
A comprehensive overview on the current state of knowledge of the endocannabinoid system as a target of pharmacotherapy is provided.
The endocannabinoid system is dysregulated in multiple sclerosis and in experimental autoimmune encephalomyelitis.
TLDR
The study suggests that targeting the endocannabinoid system might be useful for the treatment of MS, and finds that anandamide (AEA), but not 2-arachidonoylglycerol (2-AG), was increased in the CSF of relapsing MS patients, and AEA concentrations were also higher in peripheral lymphocytes of these patients.
...
1
2
3
4
5
...